Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00504400|
Recruitment Status : Completed
First Posted : July 20, 2007
Last Update Posted : September 22, 2009
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Idiopathic Macular Telangiectasia||Drug: Intravitreal injection ranibizumab||Phase 2|
Type 2 idiopathic macular telangiectasia (type 2 IMT) is a retinal disease of unknown etiology that commonly presents with a slow decrease in visual acuity, reading difficulties and metamorphopsia in the fifth to seventh decade. Diagnosis is based on fluorescein angiography which typically reveals parafoveal leakage in the late phase and may show telangiectatic capillaries in the early phase. In a subset of patients, a proliferative stage with secondary neovascularizations may develop late in the disease course. In the past, there has been no effective treatment for the disease stages without neovascularization.
Recent studies in a limited number of patients with nonproliferative disease have shown promising results after intravitreal injection of bevacizumab, an antagonist targeting vascular endothelial growth factor (VEGF). Bevacizumab resulted in a decrease of parafoveal leakage in fluorescein angiography and a decrease in retinal thickness. An increase in visual acuity was reported in a subset of patients.
The RAMA-Trial is initiated in order to investigate the effect of a ranibizumab. The safety and tolerability of this VEGF-antagonist has been extensively studied in large cohorts of patients suffering from age-related macular degeneration.
Patients with type 2 IMT will receive monthly injections over a period of one year. The above mentioned outcome measures will be assessed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Ranibizumab in Idiopathic Macular Telangiectasia, Type 2. A Prospective Interventional Non-randomized Study Comparing the Efficacy and Safety of Intravitreal Ranibizumab in Type 2 Idiopathic Macular Telangiectasia.|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||September 2009|
Drug: Intravitreal injection ranibizumab
Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
Other Name: Lucentis
- Best corrected visual acuity [ Time Frame: one year ]
- Reading ability [ Time Frame: one year ]
- Scotomas measured by means of microperimetry [ Time Frame: one year ]
- Changes in retinal thickness assessed by optical coherence tomography (OCT) imaging [ Time Frame: one year ]
- Changes in parafoveal leakage assessed by fluorescein angiography [ Time Frame: one year ]
- Quality of life [ Time Frame: one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00504400
|Department of Ophthalmology, University of Bonn|
|Principal Investigator:||Frank Holz, MD||University of Bonn, Department of Ophthalmology|
|Principal Investigator:||Hendrik PN Scholl, MD, MA||University of Bonn|